JMPWA
INKT icon

JP Morgan Private Wealth Advisors’s MiNK Therapeutics INKT Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,240
Closed -$61.4K – 1682
2023
Q1 		$61.4K Sell
3,240
-2,010
-38% -$43.5K ﹤0.01% 1909
2022
Q4 		$137K Sell
5,250
-2,900
-36% -$68.1K ﹤0.01% 1866
2022
Q3 		$172K Buy
+8,150
New +$161K ﹤0.01% 1831

Other funds holding INKT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Private Wealth Advisors's INKT Position: Q2 2023 in Review

JP Morgan Private Wealth Advisors sold out of MiNK Therapeutics (INKT) in Q2 2023, closing a stake of 3,240 shares — an estimated $61.4K sold.

JP Morgan Private Wealth Advisors first reported a position in INKT in Q3 2022 and held it in 3 quarters. The position peaked at $172K in Q3 2022. 42 funds tracked by Wall St. Rank hold INKT as of Q2 2023.

  • JP Morgan Private Wealth Advisors reported no remaining MiNK Therapeutics position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 3,240 MiNK Therapeutics shares in Q2 2023, an estimated $61.4K.
  • JP Morgan Private Wealth Advisors first reported a position in MiNK Therapeutics in Q3 2022 and held it in 3 quarters.
  • JP Morgan Private Wealth Advisors's MiNK Therapeutics position peaked at $172K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.